Transition
Therapeutics Inc. (Nasdaq: TTHI) reported disappointing results from a
Phase2/3 clinical study of ELND005 in treating agitation and aggression
in Alzheimer’s Disease patients. Shares of the biopharmaceutical plummeted $6.74 to close at $2.35.
Disappointing study results for Transition Therapeutics
June 24, 2015 at 10:14 AM EDT
